Your browser doesn't support javascript.
Utilization of smoking cessation medication benefits among medicaid fee-for-service enrollees 1999-2008.
PLoS One ; 12(2): e0170381, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28207744


To assess state coverage and utilization of Medicaid smoking cessation medication benefits among fee-for-service enrollees who smoked cigarettes.


We used the linked National Health Interview Survey (survey years 1995, 1997-2005) and the Medicaid Analytic eXtract files (1999-2008) to assess utilization of smoking cessation medication benefits among 5,982 cigarette smokers aged 18-64 years enrolled in Medicaid fee-for-service whose state Medicaid insurance covered at least one cessation medication. We excluded visits during pregnancy, and those covered by managed care or under dual enrollment (Medicaid and Medicare). Multivariate logistic regression was used to determine correlates of cessation medication benefit utilization among Medicaid fee-for-service enrollees, including measures of drug coverage (comprehensive cessation medication coverage, number of medications in state benefit, varenicline coverage), individual-level demographics at NHIS interview, age at Medicaid enrollment, and state-level cigarette excise taxes, statewide smoke-free laws, and per-capita tobacco control funding.


In 1999, the percent of smokers with ≥1 medication claims was 5.7% in the 30 states that covered at least one Food and Drug Administration (FDA)-approved cessation medication; this increased to 9.9% in 2008 in the 44 states that covered at least one FDA-approved medication (p<0.01). Cessation medication utilization was greater among older individuals (≥ 25 years), females, non-Hispanic whites, and those with higher educational attainment. Comprehensive coverage, the number of smoking cessation medications covered and varenicline coverage were all positively associated with utilization; cigarette excise tax and per-capita tobacco control funding were also positively associated with utilization.


Utilization of medication benefits among fee-for-service Medicaid enrollees increased from 1999-2008 and varied by individual and state-level characteristics. Given that the Affordable Care Act bars state Medicaid programs from excluding any FDA-approved cessation medications from coverage as of January 2014, monitoring Medicaid cessation medication claims may be beneficial for informing efforts to increase utilization and maximize smoking cessation.





Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Tabaquismo / Medicaid / Cese del Hábito de Fumar / Planes de Aranceles por Servicios / Cobertura del Seguro / Cese del Uso de Tabaco Límite: Adolescente / Adulto / Femenino / Humanos / Masculino / Media edad / Joven adulto País/Región como asunto: America del Norte Idioma: Inglés Revista: PLoS One Asunto de la revista: Ciencia / Medicina Año: 2017 Tipo del documento: Artículo País de afiliación: Estados Unidos